6 min read
Sam North
The WHO does not fully endorse the prescribing of medical cannabis for all the health concerns it can be legally prescribed for in the UK, but it does recognise that certain cannabinoids have therapeutic potential for some health conditions.
Key takeaways
Contents
The World Health Organisation is an international agency of 194 Member States. With more than 8000 active members, including doctors, epidemiologists, scientists, and managers, WHO brings together the world’s leading public health experts, allowing them to coordinate a global response to health emergencies and address the most pressing health challenges of our time.
Established in 1948 through the United Nations, its goal is to build a better, healthier future for people all over the world while also protecting the vulnerable right now.
WHO works closely with governments and other international organisations to shape health policies, set evidence-based standards for care, and provide technical support and funding for medical research.
World Health Day 2026 builds on this role, with the theme “Together for health. Stand with science”. It highlights the importance of evidence-based healthcare and global collaboration, including the One Health approach, which recognises the connection between human, animal, and environmental health.
In short, the theme of World Health Day 2026 is to promote trust in science and highlight the importance of research-led care in improving people’s health.
Yes, it is in 2026 - The WHO medical cannabis policy has evolved over time, but has historically been against the use of cannabis for medical purposes.
While the organisation's early research into the plant stayed very much in line with the political thinking of the time, there was a substantial shift in attitude in June 2018. A 'pre-review' by WHO spurred a more in-depth report of the plant's potential therapeutic applications, and the results were not what most expected.
To be clear, the WHO does not fully endorse medical cannabis. That said, it does recognise the plant's therapeutic potential. Since the 2018 review, the WHO has continued to push for evidence-based policies and promote the use of medical cannabis for a range of conditions. This role also shapes how emerging treatments, including medical cannabis, are evaluated and understood.
In short, certain cannabinoids offer a range of therapeutic benefits and have a much lower potential for harm than previously thought.
Regarding cannabidiol (CBD), the Committee advised against scheduling pure CBD products under the International Drug Control Conventions. They highlighted ongoing research into CBD's therapeutic uses across a range of clinical applications.
For THC, the recommendations were a little more reserved, but still demonstrated that the overall stance of WHO had changed.
The report also noted potential medical applications for THC, while recommending it remains within regulated frameworks.
|
Area |
WHO position |
What this means in practice |
Why it is relevant for patients |
|
CBD |
Not recommended for international drug scheduling |
It can be researched and used without the same level of restriction as controlled substances |
Supports access to research-backed treatments and reduces regulatory barriers |
|
THC |
Remains controlled under international frameworks |
It can be prescribed in regulated medical settings with strict oversight |
Available through specialist care where clinically appropriate |
|
Cannabis (overall) |
Therapeutic potential recognised, but not fully endorsed |
Considered on a case-by-case basis within evidence-led policy frameworks |
No longer dismissed outright, but assessed within clinical guidelines |
|
WHO approach |
Supports further research and evidence-based policy development |
Encourages countries to base decisions on clinical data rather than stigma |
Improves long-term access and treatment quality as evidence grows |
|
UK legal status |
Legal for medical prescription under specialist oversight since 2018 |
Classified as a Schedule 2 drug, meaning it can be prescribed but remains tightly controlled |
Patients can access treatment legally through specialist care, but not outside a clinical framework |
Scheduling is how drugs are classified.
When a drug is scheduled, regulatory bodies take into account the potential for abuse, and also any medical or therapeutic benefits. Schedules range from I-IV, with Schedule I being the most restricted and Schedule IV being the least dangerous.
In the UK, cannabis is under Schedule 2 of the Misuse of Drugs Regulations 2001. This means it’s recognised as having the potential for holding and offering therapeutic value, but is still a tightly controlled substance.
Medical cannabis is only available via specialist prescription in the UK. And while, on paper, the NHS does prescribe medical cannabis products for three very specific conditions, in practice, access through the NHS remains extremely limited.
As a result, most patients who go on to receive treatment do so through private clinics, like us here at Releaf.
This route allows specialist doctors to assess a wider range of conditions and make decisions based on individual patient history, particularly where conventional treatments have not provided sufficient relief. If you are unsure whether you might qualify, this guide on qualifying conditions for a medical cannabis prescription in the UK breaks it all down.
If you are looking to join the most trusted medical cannabis clinic in the UK, Releaf supports patients through a structured, clinician-led process. With over 6000 verified Trustpilot reviews and a rapidly growing patient base, we offer a consistent, regulated pathway into treatment, backed by a truly world-class clinical team and a fully UK-based patient support team.
The WHO’s position on medical cannabis has shifted over time, moving towards a more evidence-led view that reflects growing clinical research and real-world use.
That shift reflects a broader move towards evidence-led healthcare.
As scientific evidence improves, policies are becoming more grounded in data rather than assumption. World Health Day 2026 reinforces that direction, with a clear focus on trust in science and evidence-based healthcare.
For patients in the UK, this is already shaping access. Medical cannabis is no longer treated as a fringe treatment option, but as a regulated part of everyday healthcare when prescribed under ongoing specialist care.
If you are considering whether treatment could be suitable for you, try our medical cannabis eligibility checker. It takes less than 20 seconds, is totally free to use, and gives you a clear indication of your potential eligibility.
Releaf - Let's rethink healthcare
It is important to seek medical advice before starting any new treatments. The patient advisors at Releaf are available to provide expert advice and support. Alternatively, click here to book a consultation with one of our specialist doctors.
As of 12 August 2026, Releaf has the highest Trustpilot score, 4.8 from 9,598 reviews. Curaleaf received an overall CQC rating of ‘Good’, Alternaleaf advertises appointments for £29, while Mamedica's £200 Access Scheme is designed to potentially reduce long-term clinic costs. The right clinic for you will depend on what you value most from a clinic, but comparing the full treatment experience, rather than a single headline figure, is essential.
On the 7th July 2026, Releaf became the first medical cannabis clinic in the world to become B Corp certified. Verified by the non-profit B Lab, the certification sets in stone that Releaf is meeting the highest standard of social and environmental performance, transparency, and accountability, and has made a commitment to continue improving the way we serve not only our patients, but also our team, and the wider community.
We are proud to announce a new partnership between Releaf and brainstrust, the UK charity supporting people affected by a brain tumour. Together, we want to make sure that anyone living with a brain tumour has access to compassionate, expert care through the most trusted medical cannabis clinic in the UK. Here is what the partnership means and how patients currently in treatment can get in touch.
